Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report

Olaparib has been applied as monotherapy to treat ovarian and breast cancer patients with malignant or suspected malignant BRCA1/2 mutations. Pembrolizumab has been approved to treat unresectable or metastatic tumors in patients who exhibited progression after previous treatment, regardless of histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Fan, Gong, Jing, Wang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342556/
https://www.ncbi.nlm.nih.gov/pubmed/32753881
http://dx.doi.org/10.2147/OTT.S250454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342556/
https://www.ncbi.nlm.nih.gov/pubmed/32753881
http://dx.doi.org/10.2147/OTT.S250454

Ejemplares similares